CSC Expands its Fund Services Footprint into Ireland
Today, CSC announced its Fund Services expansion into Ireland as part of its long-term strategy to provide global clients access to our suite of Fund Administration, Capital Markets, and Depositary services. After a comprehensive six-month application process with the Central Bank of Ireland, CSC has been licensed to provide its Fund Services offering in one of the leading European financial centers.
“Ireland continues to enjoy a reputation as a dominant European and global fund administration center,” says Liam McHugh, managing director of Fund Services for CSC. “Given the current trend of consolidation and M&A activity amongst competitors, we feel we are well placed entering the market as a privately owned partner with a more than 120-year history. Our long-term stability, as well as our client centric approach, is highly valued by our clients.”
This expansion follows several strategic hires, a recent acquisition, and other investments, including the organic recruitment and launch of Fund Services businesses in the U.S. and APAC markets. McHugh will lead the Dublin office, supported by a highly experienced management team, including David Barry as head of operations, David McCormack as head of transfer agency, and Lynda Kenny as head of risk and compliance, while Paul Whelan joins to oversee our global depositary offering.
CSC has earned the trust of clients around the world, working with 60% of the top 100 global alternative asset managers, providing specialized outsourcing services to them and their advisors in the U.S., Europe, and Asia.
“Unlike other providers, one of our greatest strengths is that our professionals in the United States, Europe, and Asia-Pacific work as one team to deliver fully complementary and multi-jurisdictional solutions,” says John Hebert, senior vice president of CSC. “Our global capabilities and team-based approach enables us to work in partnership with our clients regardless of market, service, asset type, or location—so we’re positioned to make our client’s interests our top priority.”
The Irish office of Simmons & Simmons advised CSC on the licensing and approval process with the Central Bank of Ireland.
For more information about CSC’s Fund Services business, visit cscgfm.com.
CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500® , nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EURID25.5.2020 13:32:05 CEST | Press release
Closer Collaboration between the EUIPO and EURid to Benefit SMEs
TIP-TRAILER-SERVICES25.5.2020 10:07:11 CEST | Press release
TIP Trailer Services Announces Appointment of New CFO
TEVA-PHARMACEUTICAL25.5.2020 08:02:15 CEST | Press release
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
JEOL25.5.2020 08:02:15 CEST | Press release
JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT800
IPSEN23.5.2020 07:02:12 CEST | Press release
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence
MA-TAKEDA-PHARMACEUTICAL22.5.2020 22:32:04 CEST | Press release
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom